Compare GoPro Inc (GPRO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Sana Biotechnology Inc — how do they compare? GoPro Inc trades at $1.19 (market cap $243.50M), while Sana Biotechnology Inc trades at $2.81 (market cap $836.71M). The key difference: Sana Biotechnology Inc is far larger — about 3.4× GoPro Inc's market cap, and GoPro Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Sana Biotechnology Inc for 23 Days on average.
| GPRO | SANA | |
|---|---|---|
Market Cap | $243.50M | $836.71M |
Volume | 11,527,160 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $2.35 | $5.92 |
52-Week Low | $0.58 | $2.68 |
Typical Hold Time | 45 Days | 23 Days |
Enterprise Value | $302.28M | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.20, down 1.64% with a volatile trading pattern following recent merger announcements. The stock shows bullish technical signals despite negative fundamental metrics including a -28.52% net income margin and -497.15% ROE. Recent developments include a $285 million merger agreement with Starman Optical and significant retail investor interest from influencer Markiplier's 8.5% stake acquisition.
The proposed merger at $1.14 per share creates a potential exit opportunity, though current trading above this level suggests market optimism about deal terms. However, persistent negative cash flows, declining revenues, and shareholder litigation regarding deal fairness present substantial risks. The company's pivot into AI data centers offers growth potential but execution uncertainty remains high.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
